Dolutegravir

GlaxoSmithKline and Pfizer's HIV Joint Venture Gets Priority Review for Dolutegravir

GlaxoSmithKline and Pfizer's HIV Joint Venture Gets Priority Review for Dolutegravir

Motley Fool

GSK wins priority status for new HIV drug in U.S.

GSK wins priority status for new HIV drug in U.S.

Reuters

Glaxo Future Hangs in Balance on 2013 U.S. Drug Approvals

Glaxo Future Hangs in Balance on 2013 U.S. Drug Approvals

Bloomberg

Shionogi applies for HIV drug approval in U.S., Europe

Shionogi applies for HIV drug approval in U.S., Europe

Reuters

Glaxo-Pfizer HIV Drug Helps Hard-to-Treat Patients

Glaxo-Pfizer HIV Drug Helps Hard-to-Treat Patients

Bloomberg

Shionogi to take 10 pct stake in GSK, Pfizer HIV drug venture

Shionogi to take 10 pct stake in GSK, Pfizer HIV drug venture

Reuters

GlaxoSmithKline Reports Completion Of Dolutegravir Registration Package

GlaxoSmithKline Reports Completion Of Dolutegravir Registration Package

NASDAQ.com

Glaxo, Shionogi Say HIV Drug Beats Gilead Atripla In Test

Glaxo, Shionogi Say HIV Drug Beats Gilead Atripla In Test

Bloomberg

GSK Sets Stage for Big Late-Stage Drug Events, Potential Blockbusters

GSK Sets Stage for Big Late-Stage Drug Events, Potential Blockbusters

Motley Fool